Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-28 | Robyn M. Hunter has served as a director since January 2022. Our Board of Directors believes that Ms. Hunter’s general business experience and finance expertise and practice in the pharmaceutical industry, developed through her leadership at other companies, qualifies her to serve on our Board. The Board has determined that Ms. Hunter is an independent director. She serves on the Audit and Compliance Committee and the Compensation Committee. |
| 2023-04-28 | Robyn M. Hunter has served as a director since January 2022. ... Our Board of Directors believes that Ms. Hunter’s general business experience and finance expertise and practice in the pharmaceutical industry, developed through her leadership at other companies, qualifies her to serve on our Board. ... The members of the Audit and Compliance Committee are currently Drs. Almenoff and Davidson and Ms. Hunter. Ms. Hunter serves as chair of the Audit and Compliance Committee. ... The members of the Compensation Committee are currently Ms. Hunter, Dr. Davidson and Mr. Proehl. ... The following table summarizes the compensation paid to non-employee directors for fiscal year ended December 31, 2022: Robyn M. Hunter 65,000 fees earned or paid in cash, 3,259 option awards, total 68,259. |
| 2023-10-27 | Robyn M. Hunter 313 * |
| 2024-04-26 | Robyn M. Hunter has served as a director since January 2022. Our Board of Directors believes that Ms. Hunter’s general business experience and finance expertise and practice in the pharmaceutical industry, developed through her leadership at other companies, qualifies her to serve on our Board. The members of the Audit and Compliance Committee are currently Drs. Almenoff and Davidson and Ms. Hunter. Ms. Hunter serves as chair of the Audit and Compliance Committee. The members of the Compensation Committee are currently Ms. Hunter, Dr. Davidson and Mr. Proehl. The following table summarizes the compensation paid to non-employee directors for fiscal year ended December 31, 2023: Robyn M. Hunter 65,000. |
| 2024-09-27 | Robyn M. Hunter 65,000 |
Data sourced from SEC filings. Last updated: 2025-07-01